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Objectives: The site of pharmacological activity of raltegravir is intracellular. Our aim was to determine the
extent of raltegravir cellular penetration and whether raltegravir total plasma concentration (Ctot) predicts cel-
lular concentration (Ccell).
Methods: Open-label, prospective, pharmacokinetic study on HIV-infected patients on a stable raltegravir-
containing regimen. Plasma and peripheral blood mononuclear cells were simultaneously collected during a
12 h dosing interval after drug intake. Ctot and Ccell of raltegravir, darunavir, etravirine, maraviroc and ritonavir
were measured by liquid chromatography coupled to tandem mass spectrometry after protein precipitation.
Longitudinal mixed effects analysis was applied to the Ccell/Ctot ratio.
Results: Ten HIV-infected patients were included. The geometric mean (GM) raltegravir total plasma maximum
concentration (Cmax), minimum concentration (Cmin) and area under the time–concentration curve from
0–12 h (AUC0 – 12) were 1068 ng/mL, 51.1 ng/mL and 4171 ng.h/mL, respectively. GM raltegravir cellular Cmax,
Cmin and AUC0 – 12 were 27.5 ng/mL, 2.9 ng/mL and 165 ng.h/mL, respectively. Raltegravir Ccell corresponded
to 5.3% of Ctot measured simultaneously. Both concentrations fluctuate in parallel, with Ccell/Ctot ratios remain-
ing fairly constant for each patient without a significant time-related trend over the dosing interval. The
AUCcell/AUCtot GM ratios for raltegravir, darunavir and etravirine were 0.039, 0.14 and 1.55, respectively.
Conclusions: Raltegravir Ccell correlated with Ctot (r¼0.86). Raltegravir penetration into cells is low overall (5%
of plasma levels), with distinct raltegravir cellular penetration varying by as much as 15-fold between patients.
The importance of this finding in the context of development of resistance to integrase inhibitors needs to be
further investigated.
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Introduction
Raltegravir has demonstrated potent antiviral activity with so far a
favourable safety profile.1 – 6 It is associated with a much more
rapid reduction in viral load than other antiretroviral drugs
(ARVs) in treatment-naive patients,7 and has performed much
better than anticipated, even in patients with limited options
who have subtherapeutic raltegravir plasma concentrations.8 Ral-
tegravir is characterized by large intra-individual (122%) and inter-
individual (212%) pharmacokinetic variability,9 which may be
related to food composition and intake,10 pH-dependent solubility
(with higher solubility at increasing pH)11 and polymorphism of the
UDP-glucuronosyl-transferases (UGTs),12 and, as a substrate of
P-glycoprotein (P-gp), may possibly be influenced by P-gp
expression level.13,14 Given the high pharmacokinetic variability
and favourable safety profile at the recommended dose of
400 mg twice daily, relationships between raltegravir plasma
exposure and virological response or toxicity have been so far dif-
ficult to establish. No consistent pharmacokinetic/pharmacody-
namic relationships have been evidenced so far using raltegravir
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concentration in plasma,9 suggesting that other markers of ralte-
gravir exposure may better predict its pharmacological activity in
patients. Raltegravir exerts its antiviral activity within the infected
cells. However, there is at present very limited information on ral-
tegravir penetration into cells, the extent of raltegravir cellular
exposure and the relationships between raltegravir concentrations
measured in vivo in plasma and those in peripheral blood mono-
nuclear cells (PBMCs) from HIV patients.
We therefore initiated a pilot, prospective, pharmacokinetic
study to determine over one dosing interval (12 h) raltegravir
concentrations simultaneously in plasma and PBMCs in
HIV-infected patients on stable raltegravir-containing regimens.
Our aims were to assess whether raltegravir plasma concen-
trations reflect cellular levels, and to determine the overall ralte-
gravir cellular disposition, its intra- and inter-patient variability
and its correlation with plasma concentrations. Moreover, cellu-
lar disposition of etravirine, maraviroc, darunavir and ritonavir
were similarly determined in cells and in plasma from patients
receiving those drugs in combination with raltegravir.
Methods
Study design
This was an open-label, prospective, pharmacokinetic study on
HIV-infected patients on a stable salvage raltegravir-containing
regimen. The study was performed in accordance with the Declaration
of Helsinki and its amendments, and in compliance with guidelines of
good clinical practice.
Patients were admitted to the hospital at 7.15 a.m., 45 min before the
time of their morning dose of raltegravir. They received a standardized
breakfast at 7.45 a.m. before drug intake, and standardized lunch and
dinner at 12 a.m. and 7 p.m., respectively. For Ctot determination, six
blood samples (5 mL; Monovettesw with EDTA-K; Sarstedt, Nu¨mbrecht,
Germany) were collected starting at pre-dose (time 20.5 h) and 1, 3, 6,
8 and 12 h after oral administration of the drugs (time 0 h). Additional
blood samples (8 mL; Vacutainerw CPTTM cell preparation tubes with
sodium citrate; Becton Dickinson, Franklin Lakes, NJ, USA) were collected
at 20.5 h and 3, 8 and 12 h post-dose for Ccell determination. Patients
were also invited to report the exact date and time of the last three ral-
tegravir doses, the composition of the accompanying meal and the exact
date and time of the last dose of all other drugs. The following laboratory
measurements were performed at pre-dose: viral load; CD4 cell count;
serum alanine and aspartate aminotransferases; g-glucurotransferase;
amylases; alkaline phosphatase; total and direct bilirubin; glucose;
cholesterol; high- and low-density lipoprotein; triglycerides; total mag-
nesium; total calcium; albumin; creatine kinase; creatinine; full blood
cell count; and pregnancy test.
Patients
The study protocol and informed consent form were approved by the
local Ethics Committee of the University Hospital. Written informed
consent was obtained from all patients. HIV-infected adults were eligible
for inclusion if they had been on a stable raltegravir-containing antiretro-
viral regimen for at least 3 weeks. Pregnant or breastfeeding women
were not eligible.
Materials
The solvents used for chromatography and all other chemicals were of
analytical grade and used as received. Ultrapure water was obtained
from a Milli-Qw UF-Plus apparatus (Millipore Corp., Burlington, MA, USA).
PBS solution was obtained from Sigma–Aldrich (Schnelldorf, Germany).
RPMI 1640/25 mM L-glutamine medium and heat-inactivated fetal
bovine serum (FBS) used for the isolation of PBMCs from deleucocytation
filters for the preparation of matrix (see below) were obtained from Invi-
trogen (Basel, Switzerland). Ficoll Separating Solution for the separation
of blank PBMCs from other cells was obtained from Biochrom AG
(Berlin, Germany).
Total plasma and cellular concentrations
Raltegravir, darunavir, maraviroc, etravirine and ritonavir Ctot were
measured by HPLC coupled to tandem mass spectrometry (LC-MS/MS;
TSQ Quantum Ion Max; Thermo Fisher Scientific, Waltham, MA, USA)
using our validated method.15 Limits of quantification for Ctot in plasma
were 12.5 ng/mL for raltegravir, 25 ng/mL for darunavir, 10 ng/mL for etra-
virine, 2.5 ng/mL for maraviroc and 5 ng/mL for ritonavir, which correspond
to the lowest levels that could be confidently measured with a bias and
CV% below+20% (where CV stands for coefficient of variation). Cell iso-
lation from patient whole blood was performed in a Class II biohazard
hood, using gloves and long sleeves, according to our previously published
method.16,17 In brief, PBMCs were isolated by density gradient centrifu-
gation in an 8 mL CPT tube. After three successive washings of cells at
+48C with PBS containing 5% FBS to eliminate any residual plasma
absorbed onto the cell surface, the total PBMCs contained in the pellet
were counted in an aliquot using a Coulter instrument
(Cell-dynw 3500R; Abbott AG, Baar, Switzerland). Of note, the addition of
FBS to PBS washing solution was based on the recent guidelines promul-
gated by the T-Cell Workshop Committee,18 reporting that the addition
of serum proteins up to 10% to washing buffer increases the PBMC collec-
tion yield. The washed cell pellets were stored at2208C until drug extrac-
tion (MeOH/H2O 50:50). All CPT tubes were processed within 5 min after
blood withdrawal, and the total time between blood sampling and
washed cell freezing was 2 h. All sample processing was carried out
under ice-cold conditions to prevent drug loss. Ccell was determined
using an adaptation of our LC-MS/MS method15 according to the method-
ology previously described by our group.16,17 Briefly, calibration samples for
cellular determination were prepared using matrix-matched samples con-
taining white blood cells (107 cells) isolated from deleucocytation filters
obtained from the Hospital Transfusion Unit. On the day of the analysis,
white blood cells were spiked with ARV solutions containing internal stan-
dard darunavir-d9 in MeOH/H2O 50:50 to obtain calibration ranges of
0.025–80 ng/mL for each drug. A 200 mL volume of extracting solution
containing darunavir-d9 in MeOH/H2O 50:50 was added to each isolated
patient PBMC pellet. The PBMC lysates were vortexed, sonicated for
30 min for cell lysis and extracted for 30 min onto a planar vortexing–
vibrating mixer. The extracts were then centrifuged at 14000 rpm
(20000 g) for 10 min at 208C. A 200 mL volume of supernatant was intro-
duced into a microvial and a 20 mL volume was injected into the LC-MS/MS
apparatus for drug quantification. Ccell was expressed in ng/mL, according
to PBMC count, and assuming a 0.4 pL cell volume.19
Statistical analysis
The values of pharmacokinetic parameters of raltegravir, darunavir, etra-
virine, maraviroc and ritonavir were calculated by non-compartmental
pharmacokinetic methods. The maximum concentration observed in
plasma (Cmax), the time to the maximum concentration (Tmax), the
minimum concentration observed in plasma (Cmin) and the trough
(pre-dose) concentration (Ctrough) were read from the plasma
concentration–time curves. The AUC from 0–12 h (AUC0 – 12) was calcu-
lated over one dosing interval using the linear trapezoid method for
Ctot and Ccell data for each patient. The apparent plasma clearance (CL/
F, where F is the bioavailability) was calculated by dividing the adminis-
tered dose by the AUC. Additional pharmacokinetic parameters were also
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Table 1. Total and cellular pharmacokinetic parameters for raltegravir, darunavir, etravirine, maraviroc and ritonavir
Raltegravir (n¼10) Darunavir (n¼6) Etravirine (n¼4) Maraviroc (n¼2) Ritonavir (n¼6)
Total plasma parameters
AUC (ng.h/mL) 4171 56096 6225 3038 6146
range 825–14708 36853–94635 3136–14120 2276–4054 2220–9355
CV% 160 48 86 50 70
Cmax (ng/mL) 1068 7524 716 408 849
range 172–3753 4608–11721 488–1327 312–534 324–1378
CV% 166 48 54 46 75
Tmax (h) 2.0 2.5 3.6 1.7 3.8
range 1.0–6.1 1.0–3.0 3.0–6.1 1.0–3.0 3.0–6.1
CV% 114 54 42 119 43
Cmin (ng/mL) 51.1 3339 453 128 324
range 8.3–345 1580–5592 296–888 124–132 201–642
CV% 228 63 61 4 56
Ctrough (ng/mL) 40.1 2693 484 128 309
range 8.3–345 1580–3991 296–888 124–132 253–486
CV% 290 58 75 4 36
CL/F (L/h) 96 11 32 49.4 16.3
range 27–485 6–16 14–64 37–66 10–45
CV% 160 48 86 50 70
t1/2 (h) 2.4 7.5 11.5 6.6 5.0
range 1.5–3.5 5.5–11.0 7.2–18.9 4.7–9.1 4.0–6.7
CV% 27 37 60 58 24
V/F (L) 325 115 533 468 95
range 74–1717 52–203 315–940 253–864 71–135
CV% 191 79 73 138 31
Cellular parameters
AUC (ng.h/mL) 165 7642 9629 8310 11216
range 14–906 2429–16998 5168–17310 6463–10685 6922–20143
CV% 343 137 67 43 48
Cmax (ng/mL) 27.5 1373 1159 1012 1273
range 2.1–205 401–3704 476–3678 782–1311 653–3480
CV% 358 136 143 44 81
Tmax (h) 3.3 4.5 5.5 3.0 3.0
range 3.0–8.1 3.0–12.0 3.0–12.0 — 3.0–3.1
CV% 37 86 100 1 1
Cmin (ng/mL) 2.9 206 450 419 692
range 0.6–26.9 58–781 314–741 339–519 326–1491
CV% 224 175 50 35 93
Ctrough (ng/mL) 2.7 257 526 419 472
range 0.6–26.9 58–619 314–1398 339–519 326–739
CV% 286 206 133 35 44
Penetration ratios
Ccell/Ctot ratio 0.053 0.09 1.29 3.03 1.80
rangea 0.0067–0.37 0.0014–0.56 0.60–9.90 2.45–3.93 0.48–7.91
CV% 132 180 107 18 77
rangeb 0.013–0.196 0.040–0.169 0.83–3.10 2.93–3.12 0.95–4.76
CV% 111 72 84 4 71
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computed; apparent volume of distribution (V/F¼CL/F/lz) and
half-life (t1/2¼0.693/lz), where lz is the slope of the terminal elimination
phase of the log Ctot–time curve.
Geometrical means (GMs) and CVs were calculated from the average
and standard deviation of log values. Cellular penetration was expressed
as the Ccell/Ctot ratio, based on the measurements at each available time-
point where both Ccell and Ctot were simultaneously determined. Changes
in cellular penetration over the dosing interval were investigated using
ratio values calculated at different times. The correlation between Ctot
and Ccell was assessed by longitudinal mixed effects analysis.
Results
Patients
Ten patients were enrolled, all of whom had been on stable
raltegravir-containing regimens (400 mg twice daily) for at
least 3 weeks. Seven patients were male (70%) and all were Cau-
casian. Median age was 51 years (range 41–67 years) and
median CD4 cell count was 368 cells/mm3 (range 239–
839 cells/mm3). Most (9/10) patients had an undetectable viral
load (,40 copies/mL) while in one patient the viral load was
68 copies/mL. Co-administered ARVs included darunavir/ritonavir
600/100 mg twice daily (n¼6), etravirine 200 mg twice daily
(n¼4), maraviroc 150 mg twice daily (n¼2), efavirenz 600 mg
once daily (n¼1), atazanavir 400 mg once daily (n¼1), plus
emtricitabine/tenofovir (n¼5), lamivudine (n¼4) or abacavir
(n¼1).
Pharmacokinetic characteristics
Raltegravir, darunavir, etravirine, maraviroc and ritonavir phar-
macokinetic parameters determined from observed Ctot and
Ccell values are summarized in Table 1, and the GM plasma and
cellular concentrations versus time profiles are shown in
Figure 1. Both concentrations fluctuate in parallel. CVs of phar-
macokinetic parameters were considerable for raltegravir, and
significant for other drugs, consistent with the known inter-
subject pharmacokinetic variability of ARVs.
Correlation between cellular and plasma concentrations
Figure 2 shows the log–log linear correlations between Ctot and
Ccell for each drug. Good correlations were obtained for raltegra-
vir (r¼0.86) and maraviroc (r¼0.96) with a slope of the Ccell/Ctot
plot of 0.94 and 0.78, respectively. Correlations were moderate
for darunavir (r¼0.69) and ritonavir (r¼0.44), and poor for
etravirine (r¼0.26) with a corresponding slope of 1.69, 0.45
and 0.34, respectively.
Cellular penetration
Raltegravir Ccell (GM) corresponds to 5.3% of Ctot measured
simultaneously, with large inter-patient variability (range
1.3%–19.6%). Figure 3 shows the Ccell/Ctot ratios measured for
raltegravir for each patient at different times after dose adminis-
tration. Ccell/Ctot ratios varied significantly within each patient
(CV intra-patient¼83%); however, without a significant time-
related trend over the dosing interval. Ccell/Ctot ratios varied to
a larger extent between patients (CV inter-patient¼96%;
one-way ANOVA on log: P,0.001, r2¼0.62), highlighting the dis-
tinct cellular penetration of raltegravir in each patient. Raltegravir
Ccell/Ctot ratios were not influenced by the presence of other
ARVs; 0.044 without versus 0.059 with co-medication with daru-
navir/ritonavir (P¼0.57), 0.051 without versus 0.055 with
co-medication with etravirine (P¼0.89) and 0.050 without
versus 0.065 with co-medication with maraviroc (P¼0.66).
However, due to the limited number of patients, and the
high amount of variability, this investigation would have been
powered only to detect an effect size corresponding to a
factor of 3.
AUCcell corresponds to 3.9% (range: 0.7%–17.7%), 14% (7%–
38%), 155% (82%–552%), 274% (260%–280%) and 182%
(85%–534%) of AUCtot for raltegravir, darunavir, etravirine, mar-
aviroc and ritonavir, respectively (Table 1).
Discussion
Intracellular concentrations of ARVs are most likely a result of
passive transport and active uptake and efflux from cells. To
date, there has been limited information on the extent of ralte-
gravir Ccell, the impact of co-medications and whether raltegravir
Ctot predicts Ccell. The first study published in that field reported
no measurable concentrations of raltegravir in cells (i.e. below
the limit of quantification of 1 ng/mL of their assay),20 an unlikely
finding for a drug expected to act intracellularly. Conversely, a
Ccell/Ctot ratio for raltegravir of 10%, also with large variability,
was recently published in a small group of patients (n¼5),
using a once-a-day raltegravir regimen.14 In the present
study, we confirmed results from Molto´ et al.14 in a patient
group of double the size. Further, we expanded our study by
examining the importance of inter-individual variability in cellular
penetration of raltegravir and other new ARVs.
Table 1. Continued
Raltegravir (n¼10) Darunavir (n¼6) Etravirine (n¼4) Maraviroc (n¼2) Ritonavir (n¼6)
AUCcell/AUCtot ratio 0.039 0.14 1.55 2.74 1.82
range 0.007–0.177 0.07–0.38 0.82–5.52 2.6–2.8 0.85–5.34
CV% 130 99 141 5 85
n, number of patients.
Data are expressed as GMs and their associated range and CV%.
aAll measured ratios.
bIndividual patient’s GM ratios.
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We observed that plasma measurements are adequate pre-
dictors (r¼0.86) of the cellular levels of raltegravir, without
noticeable influence of co-administered ARVs. Drug interaction
studies with darunavir,21 etravirine22 and maraviroc23 have
shown a modest, not clinically significant, decrease of 30% in
raltegravir plasma exposure. This should not affect cell/plasma
ratio values because the slope close to unity for raltegravir indi-
cates that variations in plasma concentrations tend to translate
into similar changes in cellular levels. For darunavir, the slope
was 1.69 and the correlation was less precise (r¼0.69, n¼22).
Etravirine Ctot only moderately reflects the highly variable cellular
levels, suggesting that alternative factors (uptake transporters or
efflux transporters other than MDR1, etravirine being not a P-gp
substrate)24 may modulate etravirine cellular penetration. As
maraviroc is bound into transmembrane helices of its target
CCR5,25 the membrane-bound drug is analysed during measure-
ment in PBMC lysates. We found an excellent correlation
(r¼0.96) between plasma and cellular concentrations of mara-
viroc, although the number of maraviroc data in our study
were limited.
The GM cellular penetration ratios obtained for darunavir and
etravirine were 0.09 and 1.29, respectively, using concentration
ratios, and are therefore not in agreement with Ccell/Ctot values
of 1.32 and 12.9 previously published for darunavir and
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Figure 1. Total and cellular GM concentrations. RAL, raltegravir; DRV, darunavir; ETV, etravirine; MVC, maraviroc; RTV, ritonavir. Filled and open circles
represent total and cellular GM concentrations (geometric SD), respectively.
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etravirine, respectively.20 In the latter study by ter Heine et al.,20
the plasma used for the determination of total drug concen-
trations was collected directly from Vacutainerw CPT tubes.
These Vacutainerw CPT tubes contain liquid components that
dilute the plasma phase,26 which in turn will result in lower
total plasma concentrations, and hence spuriously high Ccell/
Ctot values. This issue has been verified in our laboratory in a sep-
arate set of patients’ analyses; raltegravir total plasma concen-
trations (as well as those of other ARVs) measured in plasma
collected from Vacutainerw CPT tubes were 20%–30% lower
than those determined in parallel directly in EDTA tubes (data
not shown). In fact, total plasma levels (and Cmax values)
reported in the ter Heine et al.20 study were low overall, and
were consistently below those previously published for raltegra-
vir,1,3,9 darunavir,27 – 30 etravirine24,29,31 and ritonavir.30,32 In our
study, the penetration ratio values determined in parallel for rito-
navir in the same cell pellets (i.e. 1.80, range 0.48–7.91) are in
good agreement with known values previously published for
this drug.17,33,34 Overall, the limited concordance for some cellu-
lar concentration values may be explained to some extent by
differences in the methodologies applied for the isolation/
washing of the PBMCs from blood (ter Heine et al.,20 Molto´
et al.14 and the present study). The harmonization of cell iso-
lation methods prior to intracellular drug measurement would
be welcome and ideally would be based on recently published
guidance.18
Our study shows that raltegravir cellular penetration is gener-
ally low (5% of plasma levels), and that each patient exhibited
a distinct cellular penetration for raltegravir with Ccell/Ctot ratios
ranging from 0.013 to 0.196, a 15-fold difference. This variability
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Figure 2. Correlation of Ccell versus Ctot for raltegravir (RAL), darunavir (DRV), etravirine (ETV), maraviroc (MVC) and ritonavir (RTV).
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cannot be accounted for by a limitation of analytical performance
(precision of 9.3% at the lowest calibrator of 0.025 ng/mL ralte-
gravir in PBMC lysates) or by other confounding factors (notably
cell isolation procedures) likely to affect measurements; darunavir,
ritonavir and etravirine, simultaneously determined in the same
cell pellets, had cellular penetration ratio variability differing by
only 4-fold (n¼6 patients), 5-fold (n¼6) and 3.7-fold (n¼4),
respectively. The 15-fold inter-individual variability in raltegravir
Ccell/Ctot ratios suggests therefore that alternative factors (trans-
porters or intracellular metabolism) modulate cellular levels of
raltegravir.
So far, because of the small patient numbers exhibiting viro-
logical failure in clinical trials on raltegravir, pharmacokinetic/
pharmacodynamic studies have had limited success in finding
a clear relationship between clinical response and raltegravir
exposure determined in plasma.9 Among the few patients who
exhibited incomplete viral suppression on an integrase inhibitor-
based regimen, most had no genotypic or phenotypic resistance
to integrase inhibitor during early virological failure. Resistance
emerged only in patients who remained on an integrase inhibitor
despite detectable viraemia.35 In those failing patients, raltegra-
vir concentrations in plasma were either not measured35 or, in
another study, were found not to be predictive of virological
failure, even though most failure cases occurred in patients
with low raltegravir plasma concentrations.36
In fact, the recent report published by Merck,37 on the initial
results of their Phase III study of Isentressw investigational once-
daily dosing in treatment-naive HIV-infected adults, has shown
that raltegravir 800 mg once daily is less effective (–5.7%)
than the approved 400 mg twice-daily dose, and the difference
in treatment response is primarily observed in patients with
high viral load and lower drug levels (in the once-daily arm).
For the first time, raltegravir pharmacokinetics was found to
influence virological response. This should therefore stimulate
further clinical pharmacokinetic/pharmacodynamic studies on
raltegravir and the latest ARVs.
In our study, although limited to virologically controlled HIV
patients (9 out of 10 patients), cellular penetration of raltegravir
was found to be low and characterized by significant inter-patient
variability. Raltegravir cellular penetration in the single patient for
whom viral load was not fully suppressed (68 copies/mL, patient
8) did not differ from that in the other patients studied. It is not
known at present whether in failing patients diminished raltegravir
exposure at the expected site of antiviral action may have direct
implications regarding incomplete viral suppression and long-
term treatment effectiveness. However, chronic, suboptimal cellu-
lar exposure to raltegravir may in theory permit continuing viral
evolution and the progressive emergence of raltegravir resist-
ance.35 This is certainly a relevant issue given the almost 10-fold
variability in the effective concentration inhibiting 95% of viral
replication (EC95; i.e. 2.7–22.2 ng/mL; 6–50 nM) of raltegravir
found in vitro for clinical isolates from HIV-1 patients’ PBMCs.38
In vitro studies have shown that the binding of raltegravir to
the preintegration complex (PIC) is essentially irreversible,
because the ‘off rate’ (the rate at which raltegravir dissociates
from the PIC) is longer than the half-life of the complex.39
Once binding to the PIC occurs, removing the remaining raltegra-
vir from culture does not diminish efficacy in vitro. It has been
claimed therefore that raltegravir concentrations measured in
patient plasma may be irrelevant as long as all intracellular
PICs are bound. However, in studies on raltegravir effects on
viral dynamics in patients,7 the unexpected second-phase HIV
decay by an integrase inhibitor—not supposed to influence
viral production from infected long-lived cells—was explained
by the effect of raltegravir on both long-lived infected cells and
latently infected cells with unintegrated virus.7 Since total HIV
DNA exceeds integrated HIV DNA in resting CD4 T cells by
100-fold,7 it is therefore critical that raltegravir concentration in
cells remains sufficiently therapeutic to effectively block new
productive infection upon activation of long-lived unintegrated
HIV DNA.
Thus, our study suggests that further investigations of ralte-
gravir cellular disposition are needed in the poorly defined
subset of patients in whom raltegravir fails to fully suppress
viral replication down to ,40 copies/mL, to investigate the
relationships between raltegravir cellular penetration in cells
and to study the possible constraints that may restrict raltegravir
availability to its cellular target and its impact on the levels of
both integrated and unintegrated HIV DNA in resting CD4
cells.7 More generally, because of the original action of raltegra-
vir, further investigations into not only cellular but also tissue dis-
tribution of raltegravir in various body compartments are
warranted, especially in the context of the recent trials of ralte-
gravir intensification to reduce low-level HIV replication in
plasma40 and gut.41 So far, these attempts have been of
limited success, suggesting that residual viraemia is primarily
due to HIV release from stable reservoirs (latently infected
resting CD4 memory cells and other long-lived cells), but may
possibly also arise from some cellular or tissue compartments
(i.e. ileum41) with ongoing low-level replication, for which ralte-
gravir would have limited—and variable—penetration.
The present study is among the first to provide data on cellu-
lar concentrations of raltegravir and maraviroc, but may have
some limitations: firstly, the limitation of the pilot study size;
and secondly, the measurements in total PBMCs may only
grossly reflect drug penetration in specific target cell populations,
such as CD4 T lymphocytes where HIV replicates. Third, the cell
volume used for Ccell calculation in our study (0.4 pL) may be
somewhat overestimated, as recently reported by Simiele
et al.,42 who found a lower and more variable volume for
PBMCs of between 0.23 and 0.34 pL. Ccell values reported in our
study are therefore conservative; if these recent data on cell
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Figure 3. Individual raltegravir Ccell/Ctot ratios measured in the 10
patients at different times after dose intake.
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volume are confirmed, higher Ccell values would be expected.
Finally, raltegravir may be variably embedded in membrane
lipid bilayers, complexed to cytoplasmic proteins or sequestered
through intracellular protein binding, as for HIV protease inhibi-
tors,43 so that only a small fraction of the measured cellular con-
centrations may remain available to exert the antiviral action.
Nevertheless, this cell-associated concentration remains the
best marker of viral target exposure available at the cellular
level. Obviously, drug penetration within cells is just one of the
multiple factors that influence antiviral activity besides drug
characteristics (intrinsic potency, affinity for intracellular com-
ponents and pharmacological target), overall tissue distribution,
virus characteristics (susceptibility and genotype) and host
factors (genetic background).
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